Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer

Molenaar-Kuijsten Laura, Remy B Verheijen, Bart A W Jacobs, Thijssen Bas, Rosing Hilde, Thomas P C Dorlo, Jos H Beijnen, Steeghs Neeltje, Alwin D R Huitema

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Most patients with cancer treated with everolimus experience stomatitis, which seriously affects the quality of life. The salivary concentrations of everolimus may predict the incidence and severity of stomatitis. The authors aimed to examine whether it was feasible to quantify the everolimus concentration in saliva and subsequently use it to predict stomatitis.

METHODS: Saliva and whole blood samples were taken from patients with cancer, who were treated with everolimus in the dosage of either 10 mg once a day or 5 mg twice a day. Everolimus concentrations in saliva samples were measured by liquid chromatography-tandem mass spectrometry. A published population pharmacokinetic model was extended with the everolimus concentration in saliva to assess any association between everolimus in the blood and saliva. Subsequently, the association between the occurrence of stomatitis and the everolimus concentration in saliva was studied.

RESULTS: Eleven patients were included in this study; saliva samples were available from 10 patients, including 3 patients with low-grade stomatitis. Everolimus concentrations were more than 100-fold lower in saliva than in whole blood (accumulation ratio 0.00801 and relative standard error 32.5%). Interindividual variability (67.7%) and residual unexplained variability (84.0%) were high. The salivary concentration of everolimus tended to be higher in patients with stomatitis, 1 hour postdose ( P = 0.14).

CONCLUSIONS: Quantification of the everolimus concentration in saliva was feasible and revealed a nonsignificant correlation between everolimus concentration in the saliva and the occurrence of stomatitis. If future research proves this relationship to be significant, the everolimus concentration in the saliva may be used as an early predictor of stomatitis without invasive sampling. Thereby, in patients with high salivary everolimus concentrations, precautions can be taken to decrease the incidence and severity of stomatitis.

Original languageEnglish
Pages (from-to)520-526
Number of pages7
JournalTherapeutic drug monitoring
Volume44
Issue number4
Early online date27 Jan 2022
DOIs
Publication statusPublished - Aug 2022

Keywords

  • Everolimus/adverse effects
  • Feasibility Studies
  • Humans
  • Neoplasms/drug therapy
  • Quality of Life
  • Saliva
  • Stomatitis/chemically induced
  • biomarker
  • everolimus
  • saliva
  • stomatitis
  • toxicity

Fingerprint

Dive into the research topics of 'Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer'. Together they form a unique fingerprint.

Cite this